Comparison of combined low-dose hormone therapy vs. tibolone in the prevention of bone loss

References

• Kalder M, Hadji P. Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer. Breast Care (Basel) 2014;9:312–17
   PubMed Web of Science ®Google Scholar
• Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646–50
   PubMed Web of Science ®Google Scholar
• Richelson LS, Wahner HW, Melton LJ, III, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984;311:1273–5
   PubMed Web of Science ®Google Scholar
• Ravn P, Rix M, Andreassen H, Clemmesen B, Bidstrup M, Gunnes M. High bone turnover is associated with low bone mass and spinal fracture in postmenopausal women. Calcif Tissue Int 1997;60:255–60
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729–38
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
   PubMed Web of Science ®Google Scholar
• Stevenson JC. Prevention of osteoporosis: one step forward, two steps back. Menopause Int 2011;17:137–41
   PubMedGoogle Scholar
• de Villiers TJ. 8th Pieter van Keep Memorial Lecture. Estrogen and bone: have we completed a full circle? Climacteric 2014;17(Suppl 2):4–7
   PubMed Web of Science ®Google Scholar
• Farr JN, Khosla S, Miyabara Y, Miller VM, Kearns AE. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab 2013;98:E249–57
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;16:372–9
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;59:2–6
   PubMed Web of Science ®Google Scholar
• Ziller M, Herwig J, Ziller V, Kauka A, Kostev K, Hadji P. Effects of a low-dose oral estrogen only treatment on bone mineral density and quantitative ultrasonometry in postmenopausal women. Gynecol Endocrinol 2012;28:1002–5
   PubMed Web of Science ®Google Scholar
• Riis BJ, Lehmann HJ, Christiansen C. Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs. A review. Am J Obstet Gynecol 2002;187:1101–16
   PubMed Web of Science ®Google Scholar
• Albertazzi P, Di MR, Zanardi E. Tibolone: a review. Maturitas 1998;30:295–305
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697–708
   PubMed Web of Science ®Google Scholar
• Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135–46
   PubMed Web of Science ®Google Scholar
• Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int 2002;13:241–8
   PubMed Web of Science ®Google Scholar
• Hadji P, Hars O, Bock K, et al. Age changes of calcaneal ultrasonometry in healthy German women. Calcif Tissue Int 1999;65:117–20
   PubMed Web of Science ®Google Scholar
• Hadji P, Hars O, Wuster C, et al. Stiffness index identifies patients with osteoporotic fractures better than ultrasound velocity or attenuation alone. Maturitas 1999;31:221–6
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Saeger U, Ziller V, Bauer T, Seker-Pektas B, Hadji P. The effect of age, sex hormones, and bone turnover markers on calcaneal quantitative ultrasonometry in healthy German men. J Clin Densitom 2013;16:320–8
   PubMed Web of Science ®Google Scholar
• Dufour R, Winzenrieth R, Heraud A, Hans D, Mehsen N. Generation and validation of a normative, age-specific reference curve for lumbar spine trabecular bone score (TBS) in French women. Osteoporos Int 2013;24:2837–46
   PubMed Web of Science ®Google Scholar
• Kalder M, Kyvernitakis I, Albert US, Baier-Ebert M, Hadji P. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy. Osteoporos Int 2015;26:353–60
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135–41
   PubMed Web of Science ®Google Scholar
• Eastell R, Adams J, Clack G, et al. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Ann Oncol 2011;22:857–62
   PubMed Web of Science ®Google Scholar
• Nicks KM, Fujita K, Fraser D, et al. Deletion of estrogen receptor beta in Osteoprogenitor cells increases trabecular but not cortical bone mass in female mice. J Bone Miner Res 2016;31:606–14
   PubMed Web of Science ®Google Scholar
• Abdalla HI, Hart DM, Lindsay R, Leggate I, Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985;66:789–92
   PubMed Web of Science ®Google Scholar
• Christiansen C, Riis BJ, Nilas L, Rodbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet 1985;2:800–1
   PubMed Web of Science ®Google Scholar
• Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005;12:741–8
   PubMed Web of Science ®Google Scholar
• Kyvernitakis I, Kostev K, Hars O, Albert US, Kalder M, Hadji P. Persistency with estrogen replacement therapy among hysterectomized women after the Women's Health Initiative study. Climacteric 2015;18:826–34
   PubMed Web of Science ®Google Scholar
• Hadji P, Imani P, Wuster C, Hars O, Albert US, Kyvernitakis I. Comparison of dual-energy X-ray absorptiometry with six quantitative ultrasonometry devices in women with hip fractures. Climacteric 2015;18:411–18
   PubMed Web of Science ®Google Scholar